Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Eleonora Marostica"'
Autor:
Martijn vanNoort, Martijn Ruppert, Joost DeJongh, Eleonora Marostica, Rolien Bosch, Emir Mešić, Nelleke Snelder
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 7, Pp 1170-1179 (2024)
Abstract In pharmacometric modeling, it is often important to know whether the data is sufficiently rich to identify the parameters of a proposed model. While it may be possible to assess this based on the results of a model fit, it is often difficul
Externí odkaz:
https://doaj.org/article/e80746c66672430b9aa2571b5c7e641f
Autor:
Richard Hooijmaijers, Ridhi Parasrampuria, Eleonora Marostica, Geraldine Ferron‐Brady, Teun M. Post, Sandra A. G. Visser
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 11, Pp 1602-1618 (2023)
Abstract Establishing a dosing regimen that maximizes clinical benefit and minimizes adverse effects for novel therapeutics is a key objective for drug developers. Finding an optimal dose and schedule can be particularly challenging for compounds wit
Externí odkaz:
https://doaj.org/article/96dc123b4b514d36af8c07bddd333909
Autor:
Stefan Willmann, Eleonora Marostica, Nelleke Snelder, Alexander Solms, Markus Jensen, Maximilian Lobmeyer, Anthonie W. A. Lensing, Claudette Bethune, Erin Morgan, Rosie Z. Yu, Yanfeng Wang, Shiangtung W. Jung, Richard Geary, Sanjay Bhanot
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 890-901 (2021)
Abstract IONIS‐FXIRX (BAY2306001) is an antisense oligonucleotide that inhibits the synthesis of coagulation factor XI (FXI) and has been investigated in healthy volunteers and patients with end‐stage renal disease (ESRD). FXI‐LICA (BAY2976217)
Externí odkaz:
https://doaj.org/article/a0f07a9e368749df85e58f6529f928d9
Publikováno v:
In Land Use Policy December 2017 69:519-528
Autor:
Sanjay Bhanot, Eleonora Marostica, Maximilian Lobmeyer, Nelleke Snelder, Erin E. Morgan, Anthonie W. A. Lensing, Richard S. Geary, Markus Jensen, Shiangtung W. Jung, Yanfeng Wang, Rosie Z. Yu, Stefan Willmann, Claudette Bethune, Alexander Solms
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 890-901 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
IONIS‐FXIRX (BAY2306001) is an antisense oligonucleotide that inhibits the synthesis of coagulation factor XI (FXI) and has been investigated in healthy volunteers and patients with end‐stage renal disease (ESRD). FXI‐LICA (BAY2976217) shares t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c833bb12274e461ae57144f261c44b4
https://doaj.org/article/a0f07a9e368749df85e58f6529f928d9
https://doaj.org/article/a0f07a9e368749df85e58f6529f928d9
Autor:
Ard Teisman, Filip De Ridder, Karel Van Ammel, Koen Boussery, Jan Van Bocxlaer, David J. Gallacher, Eleonora Marostica, An Vermeulen
Publikováno v:
The AAPS Journal. 18:1000-1012
Inhibiting the human ether-a-go-go-related gene (hERG)-encoded potassium ion channel is positively correlated with QT-interval prolongation in vivo, which is considered a risk factor for the occurrence of Torsades de Pointes (TdP). A pharmacokinetic/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d78af59a77dccf81ed980281d8a8a0d
https://doi.org/10.1208/s12248-016-9920-3
https://doi.org/10.1208/s12248-016-9920-3
Publikováno v:
Clinical Pharmacokinetics
Background In the OPTIMIZE study, 4 weeks of roflumilast 250 µg once daily before escalation to the approved 500 µg once daily maintenance dose reduced treatment discontinuations and improved tolerability to roflumilast among patients with chronic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b812d6e4453207afd88ba5d7ce3d780
https://pubmed.ncbi.nlm.nih.gov/29797235
https://pubmed.ncbi.nlm.nih.gov/29797235
Autor:
Karel Van Ammel, Ard Teisman, An Vermeulen, Eleonora Marostica, Jan Van Bocxlaer, Koen Boussery, David J. Gallacher, Filip De Ridder
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 42:659-679
Safety pharmacology studies are performed to assess whether compounds may provoke severe arrhythmias (e.g. Torsades de Pointes, TdP) and sudden death in man. Although there is strong evidence that drugs inducing TdP in man prolong the QT interval in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22fec7573a77a8024945aaf330ec617f
https://doi.org/10.1007/s10928-015-9434-0
https://doi.org/10.1007/s10928-015-9434-0
Publikováno v:
Mathematical Biosciences. 261:37-47
This paper addresses the problem of modelling longitudinal data describing patients’ responses in clinical trials. In particular, a systematic approach relying on a system theoretic paradigm is proposed to deal with contexts where limited physiopat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1823601894cbaa19b4c71aa60b6f113c
https://doi.org/10.1016/j.mbs.2014.11.007
https://doi.org/10.1016/j.mbs.2014.11.007
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 41:625-638
The aim of this paper is to provide a systematic methodology for modelling longitudinal data to be used in contexts of limited or even absent knowledge of the physiological mechanism underlying the disease time course. Adopting a system-theoretic par
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07bb1606336118da44c8de743bb8c0ce
https://doi.org/10.1007/s10928-014-9389-6
https://doi.org/10.1007/s10928-014-9389-6